Search Results - mechanism+of+action+biomarker

8 Results

Sort By:

Cell-Permeable Protein Therapeutic for Pain and Itch

Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...

Published: 5/9/2024 | Inventor(s): Hao-Jui Weng, Xinzhong Dong

Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain

Novel Therapeutic Target for Neural Regeneration, Stroke and Anti-depressants

Unmet needCurrent anti-depressants in the market have various limitations including lack of broad-spectrum drugs, unexpected side effects, toxicity and low efficacy for certain patients. New generation of anti-depressants based on most recent biomedical discoveries concerning depression are urgently needed. Technology overviewJohns Hopkins researchers...

Published: 5/9/2024 | Inventor(s): Dengke Ma, Guo-li Ming, Hongjun Song

Keywords(s): Biomarker, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Psychiatric Diseases, Stroke, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Stroke, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Diagnostics, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Targets

Treatment of Drug Abuse by Preventing GAPDH Nitrosylation

C12097: Novel Treatment for Cocaine Drug AbuseNovelty: A novel therapeutic strategy for cocaine abuse using known compounds.Value Proposition: Cocaine is a powerful addictive stimulant that causes psychological dependence and brain damage. Currently there are no FDA-approved drug for cocaine addiction and overdose, even though it is one of the most...

Published: 5/9/2024 | Inventor(s): Solomon Snyder, Risheng Xu, Nilkantha Sen

Keywords(s): Addiction, Biomarker, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Psychiatry > Addiction, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Therapeutic Modalities

Angiotensin Receptor as a Therapeutic Target for Autism Disorder

C11584: Diagnosis and of Autism based on Specific Receptor SiteNovelty: This invention is a new method to test pregnant mothers for an increased risk of having autistic children. The identification of this receptor-specific antibody suggests that specific inhibitors, antibodies, or other agents can be used as a therapy for autism.Value Proposition:...

Published: 5/9/2024 | Inventor(s): Tongguang Wang, Christina Morris-Berry, Harvey Singer, Avindra Nath

Keywords(s): Autism, Biomarker, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Psychiatry > Autism, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Therapeutic Modalities

C11355: Therapeutic Alleviating Cognitive Impairment from Multiple Sclerosis (MS)

Novelty:This technology is a first of its kind, potential therapeutic in alleviating cognitive impairment (CI) as a result of Multiple Sclerosis (MS) and related central nervous system (CNS) autoimmune diseases.Value Proposition:CI is a debilitating outcome of many CNS disorders, including MS. Currently, the high prevalence of CI and the extremely negative...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Kristen Hollinger, Adam Kaplin

Keywords(s): Antagonists/Inhibitors, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Cognitive Impairment, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Mechanism of Action Biomarker, Multiple CNS Indications, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Novel Compounds targeting GAPDH-Siah Cell Death Cascade

C11114: Novel Compounds targeting GAPDH-Siah Cell Death Cascade Novelty: The GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)-Siah cell death cascade is a implicated in several stress mediated disorders and blocking this cascade using novel inhibitors is an attractive strategy for developing cytoprotective agents. Value Proposition: Cell death...

Published: 5/9/2024 | Inventor(s): Neelam Shahani, Toshiaki Saito, David Kass, Eiki Takimoto, Akira Sawa

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Biomarker, CNS and Neurological Disorders, Disease Indication, Huntington's Disease, Mechanism of Action Biomarker, Neurodegenerative Diseases, Non-novel, Novel, Predicted Novelty, Psychiatric Diseases, Repurposed, Schizophrenia, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Psychiatry > Schizophrenia, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Huntington's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

Chloroquine-induced Itch is Mediated by Mrgs

C10519: Methods and Compositions for Treating Itch Value Proposition: Inventors have identified a cell receptor family known as Mrgprs that is exclusively expressed in a small subset of neurons. In vitro and animal studies suggest that the Mrg receptor family directly mediates chloroquine (CQ) induced itch. Identification and characterization of Mrgprs...

Published: 5/9/2024 | Inventor(s): David Anderson, Qin Liu, Xinzhong Dong

Keywords(s): Biomarker, CNS and Neurological Disorders, Disease Indication, Infectious Diseases, Inflammatory Disorders, Itch, Malaria, Mechanism of Action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Inflammation, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Neurology > Itch

Developing Anti-cancer Drugs by Blockade of IP6-HSP90 Binding

C05044: Developing Anti-cancer Drugs by Blockade of IP6-HSP90 BindingValue Proposition: A cellular enzyme known as inositol pyrophosphate 6 kinase 2 (IP6K2) has an important role in programmed cell death (apoptosis). JHU scientists discovered an interaction between IP6K2 and a protein known as Heat Shock Protein-90 (HSP90). Binding of IP6K2 with HSP90...

Published: 5/9/2024 | Inventor(s): Randen Patterson, Krishna Juluri, Katherine Sixt, Asif Mustafa, Damian Van Rossum, Anutosh Chakraborty, Michael Koldobskiy, Solomon Snyder

Keywords(s): Biomarker, Cancers, Cell Lines, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, Mechanism of Action Biomarker, Non-novel, Predicted Novelty, Repurposed, Target-based Screening Tool, Therapeutic Matter, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Technology Classifications > Research Tools > Human Cell Lines, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Research Tools > Assays